We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen’s Alzheimer’s Drug Loses a Vocal Critic on FDA Advisory Committee
Biogen’s Alzheimer’s Drug Loses a Vocal Critic on FDA Advisory Committee
In an unusual move, the FDA has removed an advisory committee member temporarily, just days before a critical vote on an investigational treatment for Alzheimer’s disease.